New CAR t-cell therapy takes on hard-to-treat leukemia
NCT ID NCT06281847
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a new treatment called CCTx-001 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. CCTx-001 is a type of immunotherapy that uses a patient's own immune cells, modified to target a protein called IL-1RAP found on leukemia cells. The trial has two phases: the first finds the safest dose, and the second checks how well it works. About 143 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CCTx-001 (a CAR T-cell therapy targeting IL-1RAP)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. CAR T-cell therapies can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Besançon Regional and University Hospital
Besançon, France
Contact
Contact
-
Hospital Saint Louis
Paris, France
Contact
Contact
-
Karolinska University Hospital
Stockholm, Sweden
Contact
Contact
-
Ludwig-Maximilians University of Munich
Munich, Germany
Contact
Contact
-
University Hospital Ulm
Ulm, Germany
Contact
Contact
-
Vall d'Hebron University Hospital
Barcelona, Spain
Contact
Contact